Blood Glucose Monitoring Bgm Devices Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The BGM Devices market covers hardware and consumables that allow patients and clinicians to measure blood glucose levels, including traditional finger-stick meters, test strips, lancets, and continuous glucose monitoring systems. The market is currently valued at roughly $18.33 billion in 2025 and is projected to grow at an 8.31% CAGR through the next decade, driven by an expanding diabetic population and broader access to monitoring tools. North America holds the largest share today, while Asia-Pacific is emerging as the fastest-growing region.

• •Market size in 2025 is approximately $18.33 billion with an 8.31% annual growth rate.
• •CGM technology is rapidly gaining share against conventional self-monitoring meters.
• •Asia-Pacific is projected to record the highest regional growth through 2031.

Rising diabetes prevalence worldwide remains the single largest demand driver, with more than half a billion people living with the disease and numbers climbing sharply in low- and middle-income countries. Aging populations in developed economies, growing awareness of glycemic control, reimbursement expansion for CGM, and increasing healthcare spending further reinforce growth. The shift from episodic finger-stick testing to real-time continuous monitoring is also expanding the addressable market per patient.

• •Global diabetes prevalence continues to climb, particularly in Asia-Pacific and parts of Latin America.
• •Reimbursement reforms in the U.S., Europe, and parts of Asia are making CGM devices more accessible.
• •Greater physician emphasis on tight glycemic control boosts prescription volumes for monitoring devices.

By product, the market splits into self-monitoring blood glucose devices (meters, strips, lancets) and continuous glucose monitoring systems, with CGM now representing the fastest-growing and most innovative segment. End users include home-care settings, hospitals and clinics, and diagnostic laboratories, with home-care dominating overall volumes. Geographically, North America leads in revenue, followed by Europe, while Asia-Pacific is forecast to post the strongest CAGR over the coming years.

• •CGM is the fastest-growing product category, while test strips remain the largest revenue contributor by volume.
• •Home-care is the dominant end-user segment due to the shift toward self-management of diabetes.
• •North America holds the leading regional share, with Asia-Pacific expected to expand most rapidly.

What are the recent trends and outlook?

The most significant trend is the ongoing migration from finger-stick testing toward CGM and minimally invasive or non-invasive wearable sensors. Integration with smartphones, smartwatches, insulin pumps, and diabetes-management apps is becoming standard, supporting automated insulin delivery ecosystems. Looking ahead, expect broader CGM coverage in type 2 diabetes, improved sensor accuracy and wear time, growing adoption in emerging markets, and continued M&A activity as larger players acquire specialized sensor companies.

• •CGM is expanding from type 1 into type 2 diabetes and adjacent wellness applications.
• •Sensor miniaturization, longer wear times, and AI-driven analytics are key innovation vectors.
• •The market is projected to exceed $26 billion by the mid-2030s on continued 8%+ annual growth.